Cited 2 time in
Development of Neurodegenerative Disease Diagnosis and Monitoring from Traditional to Digital Biomarkers
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Song, Jaeyoon | - |
| dc.contributor.author | Cho, Eunseo | - |
| dc.contributor.author | Lee, Huiseop | - |
| dc.contributor.author | Lee, Suyoung | - |
| dc.contributor.author | Kim, Sehyeon | - |
| dc.contributor.author | Kim, Jinsik | - |
| dc.date.accessioned | 2025-03-12T06:00:16Z | - |
| dc.date.available | 2025-03-12T06:00:16Z | - |
| dc.date.issued | 2025-02 | - |
| dc.identifier.issn | 2079-6374 | - |
| dc.identifier.issn | 2079-6374 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/57948 | - |
| dc.description.abstract | Monitoring and assessing the progression of symptoms in neurodegenerative diseases, including Alzheimer's and Parkinson's disease, are critical for improving patient outcomes. Traditional biomarkers, such as cerebrospinal fluid analysis and brain imaging, are widely used to investigate the underlying mechanisms of disease and enable early diagnosis. In contrast, digital biomarkers derived from phenotypic changes-such as EEG, eye movement, gait, and speech analysis-offer a noninvasive and accessible alternative. Leveraging portable and widely available devices, such as smartphones and wearable sensors, digital biomarkers are emerging as a promising tool for ND diagnosis and monitoring. This review highlights the comprehensive developments in digital biomarkers, emphasizing their unique advantages and integration potential alongside traditional biomarkers. | - |
| dc.format.extent | 22 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | MDPI | - |
| dc.title | Development of Neurodegenerative Disease Diagnosis and Monitoring from Traditional to Digital Biomarkers | - |
| dc.type | Article | - |
| dc.publisher.location | 스위스 | - |
| dc.identifier.doi | 10.3390/bios15020102 | - |
| dc.identifier.scopusid | 2-s2.0-85218441959 | - |
| dc.identifier.wosid | 001430571600001 | - |
| dc.identifier.bibliographicCitation | Biosensors, v.15, no.2, pp 1 - 22 | - |
| dc.citation.title | Biosensors | - |
| dc.citation.volume | 15 | - |
| dc.citation.number | 2 | - |
| dc.citation.startPage | 1 | - |
| dc.citation.endPage | 22 | - |
| dc.type.docType | Review | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Chemistry | - |
| dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
| dc.relation.journalResearchArea | Instruments & Instrumentation | - |
| dc.relation.journalWebOfScienceCategory | Chemistry, Analytical | - |
| dc.relation.journalWebOfScienceCategory | Nanoscience & Nanotechnology | - |
| dc.relation.journalWebOfScienceCategory | Instruments & Instrumentation | - |
| dc.subject.keywordPlus | MILD COGNITIVE IMPAIRMENT | - |
| dc.subject.keywordPlus | CSF ALPHA-SYNUCLEIN | - |
| dc.subject.keywordPlus | QUALITY-OF-LIFE | - |
| dc.subject.keywordPlus | PARKINSONS-DISEASE | - |
| dc.subject.keywordPlus | CEREBROSPINAL-FLUID | - |
| dc.subject.keywordPlus | ALZHEIMERS-DISEASE | - |
| dc.subject.keywordPlus | APOE GENOTYPE | - |
| dc.subject.keywordPlus | GAIT ANALYSIS | - |
| dc.subject.keywordPlus | MOTOR | - |
| dc.subject.keywordPlus | TAU | - |
| dc.subject.keywordAuthor | digital biomarker | - |
| dc.subject.keywordAuthor | neurodegenerative disease | - |
| dc.subject.keywordAuthor | traditional biomarker | - |
| dc.subject.keywordAuthor | monitoring | - |
| dc.subject.keywordAuthor | point of care | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
